Objective To systematically investigate the pooled prevalence of Small Intestinal Bacterial Overgrowth (SIBO) in patients with Irritable Bowel Syndrome (IBS) compared to healthy individuals and to evaluate the therapeutic efficacy of rifaximin in IBS patients with concomitant SIBO. Methods A comprehensive computer-based search was conducted across databases including PubMed and Embase from their inception until December 2025. Relevant cohort studies, case-control studies, and cross-sectional studies were included. Study quality was assessed using the Newcastle-Ottawa Scale (NOS). Meta-analysis was performed using a random-effects model. Results A total of 25 studies were included. The pooled risk of SIBO was significantly higher in IBS patients compared to healthy controls (OR = 5.71, 95% CI: 3.45–9.45). The Glucose Hydrogen Breath Test (GBT) subgroup showed a higher odds ratio and lower heterogeneity. Rifaximin treatment achieved a pooled SIBO eradication rate of 59% (95% CI: 0.48–0.68), with the medium-to-high dose group (≥ 1,200 mg/day) showing a slightly superior efficacy compared to the lower-dose group. Conclusion A significant association exists between SIBO and IBS. Rifaximin is an effective treatment for IBS patients with concomitant SIBO. The substrate choice for SIBO diagnosis involves a trade-off: while GBT offers greater diagnostic stability and specificity, LBT provides broader sensitivity for distal overgrowth. This evidence-based nuance should guide clinical substrate selection based on the diagnostic priority. Systematic review registration INPLASY.COM , identifier NPLASY202630002.
Huigang Lu (Tue,) studied this question.